Douglas Hunt
Vermogen: 945 350 $ op 31-05-2026
Vermogen: 945 350 $ op 31-05-2026
Mr. Douglas Hunt is a Chief Regulatory Affairs Officer at Puma Biotechnology, Inc. Mr. Hunt was previously employed as a VP-Regulatory Affairs & Quality Assurance by ArmaGen, Inc., a Vice President-Global Regulatory Affairs by Baxter Healthcare Corp., and an Executive Director-Therapeutic Area by Amgen, Inc. He received his undergraduate degree from the University of Portsmouth.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 13-04-2026 | 131.848 ( 0,26% ) | 945 350 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Algemeen Adviseur | 01-01-2018 |
| Bedrijven | Functie | Einde |
|---|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | Algemeen Adviseur | 01-12-2017 |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Algemeen Adviseur | 01-03-2015 |
| AMGEN INC. | Corporate Officer/Principal | 01-07-2008 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Develops, manufactures and distributes hospital supplies and medical technologies | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Pharmaceuticals: MajorHealth Technology Develops neurological therapies | Health Technology |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau